PYNNACLE Phase II clinical trial protocol: rezatapopt monotherapy for advanced or metastatic solid tumors with a TP53 Y220C mutation

This Clinical Trial Protocol, published in Future Oncology, describes the Phase I/II PYNNACLE study that is investigating rezatapopt for patients with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Rezatapopt works by binding with high affinity to the mutated p53 Y220C protein and stabilizing the protein structure in the wild-type p53 conformation.